

**Meeting Notes from April 17, 2015**

**MEETING FACILITATOR:** Michael Landen

**ADVISORY COUNCIL MEMBERS PRESENT:** Michael Landen, Steven Seifert, Ernie Dole, Joanna Katzman

**OTHER PARTICIPANTS:** Brandon Warrick, Carolyn Roberts, Rollin Oden, Daniel Still, Maureen Wilks, Elaine Brightwater, Linda Siegle, Carl Flansbaum, Cecilia Ruberto, Sandra Adondakis, Irene Ortiz, Randy Marshall, Annie Jung, Anisah Adnan, Kresta Antillon, Jim Davis, Luigi Garcia Saavedra, Laura Tomedi, Robin Swift

**I. Introductions and Review of Agenda**

(There was no quorum.)

**II. Review of 1/9/2015 Advisory Council Meeting Notes**

**III. Review of 2014 Recommendations**

- Soon to be mailed to state legislators
- Other ways of disseminating if people are interested?
- Maureen W. suggested press release and Mike L. responded that this would be considered.

1. *The University of New Mexico (UNM) Health Sciences Center should include substantial training in curricula regarding effectively treating pain and safe prescribing of opioids and other controlled substances.* Dr. Flores will provide a curriculum summary at the next Council meeting. Mike L.: We can send this on to all schools, nursing, pharmacy, medical, etc.

2. *The Department of Health (DOH) should collaborate with other state agencies, local governments and community partners to assure broad access to naloxone in clinical, pharmacy, and community-based venues.* Mike L.: DOH is working on a more comprehensive and expanded approach -- Will report back to Advisory Council at later time.

3. *DOH should support naloxone policy development with community-based overdose prevention efforts and public safety agencies, including state, county and municipal law enforcement.* Mike L.: Will include this in a later report to the Advisory Council.

4. *The New Mexico State Legislature should designate a new Advisory Council membership slot for the Prescription Monitoring Program director (in addition to the Board of Pharmacy representative).* Mike L.: Missed this year's session - will talk about at later point.

5. *The New Mexico Congressional Delegation should support the expansion of buprenorphine prescriptive authority to include all mid-level practitioners who have received proper training.* Rollin Oden: Senator Udall's "Increasing the Safety of Prescription Drug Use Act" bill calls for prescriptive authority for mid-levels, and to take the cap off of the number of patients treated by a provider. Mike L.: We'll keep following this issue.

6. *The health care provider licensing boards should encourage prescribers to use office-based and/or lab-based toxicology testing for the purpose of chronic opioid medication treatment plan monitoring.* Mike: This recommendation needs a next step.

7. *All licensing boards whose members include controlled substance prescribers should develop a process to monitor the utilization of the Prescription Drug Monitoring Program by their licensees in accordance with board rules.* Mike L.: We should set up meetings with boards for further discussion this year.

8. *The DOH and UNM Health Sciences Center should conduct an anonymous survey of chronic pain patients to address what their needs might be and learn more about this patient pool.* Maureen W. pursued House Memorial in 2015 session and it was passed. Mike L.: Instrument and sampling approach will be drafted, we can bring back to Advisory Council for review and comment.

9. *The Office of Medical Investigator and DOH should implement a Drug Overdose Death module in the National Violent Death Reporting System.* Laura T.: DOH is writing this into the new NVDRS federal grant proposal for budget support to do this.

10. *Licensing boards should recommend that providers consider non-opioid & non-pharmacological treatment before opioids are prescribed for chronic pain patients.* Mike: 6, 7 and 10 as a licensing package – Elaine, you could help out with this.

- Mike L.: So this is our starting point – make progress on them, refine them and come up with new ones for next year.
- Rollin: The Udall bill includes direction to FDA to switch naloxone to a “behind the counter” medication, like Sudafed or Plan B.

#### **IV. Review of PMP provider Report Card Prototype – Carl Flansbaum**

- Grouping prescribers much more than is done now – to see how they rank in relationship to their own specialty field. Color coding to correspond with outliers Beta-testing will begin in October of 2015; The plan is to produce individual provider report cards on a quarterly basis and e-mailed as a PDF attachment to providers
- Unsolicited reports are being issued quarterly and sent to prescribers (When one of their patients is accessing care from at least 5 medical providers and filling prescriptions in at least 5 pharmacies). Eventually, this will come up as automatic alert on the PMP when that threshold (5 providers and 5 pharmacies for single patient) is reached.
- Mike L.: We will continue to refine this over time. Great work ... we'll keep moving forward.

#### **V. Review of Legislative Session**

- Mike L.: There was a memorial passed on drug take back. Senate Joint Memorial 23 would have requested this Council to convene a working group of stakeholders to analyze and make recommendations relating to the state's options for establishing an unused prescription drug recovery program. (Senate Bill 21 would have provided for the collection and disposal of unused dangerous drugs. It would have required the Board of Pharmacy to require each retail pharmacy to collect unused drugs, provide for their safe disposal, and establish a means of funding.) Mike asked whether there were any volunteers to lead this?
- Maureen's House Memorial 98, requesting DOH to collaborate with the UNM Health Sciences Center Pain Center to design a survey of chronic pain patients to ascertain their needs in an effort to reduce overdose deaths from prescription drugs, passed.
- Pain Relief Act Revision Bill (did not get passed): Randy Marshall presenting. SB422, sponsored by Senator Beffort. Randy summarized concerns and intent of proposed bill including a peer review panel to support board response to identified outlier prescription writing.
- Mike L.: Revision of Pain Relief Act in 2012 – maybe the Advisory Council should review the Act and consider further revision? Approach consensus on improvements to the Act.
- Joanna K.: UNM Chronic Pain Clinic bill, SB24, got line item vetoed after \$50K was incorporated into the General Appropriation Act.

#### **VI. Proposed By-Laws**

- Draft By-Laws document circulated to all members and participants.

- Mike L.: Key issue on Page 2: “council recommendations” and “conflict of interest”. Right now, anybody can make a recommendation to this group, not just members. Some suggestion at the last meeting that we should limit to members. How do people feel about “Only members of the Council ...”
- Mike L.: We’ll revise to add the language “propose recommendations” and vote at the next meeting.

## **VII. OTHER**

- Carrie: from Santa Fe Opioid Safe planning group – identifying high prescribers to convince them to check PMP. Suggestion of letter from licensure boards – Informing individual prescribers that they have been identified as “a prescriber not checking PMP.” Steve J: NMMB is already doing that.
- Rollin O.: Proposed presentation to Council on the ethics of prescribing opioids and not providing access to opiate replacement therapy
- Steve J.: Presbyterian is attempting to address issue of new providers who are discharging pain patients, with Opioid Summit at the end of the month – talking about responsibility of providers to address pain. Pushing on this responsibility that providers shouldn’t “fire” the patients.
- Joanna K. – Presentation on co-prescription pilot at Pain Clinic.

## **VIII. NEXT MEETING**

- Mike: Agenda items for next meeting – Present 2014 mortality and prescribing data; Ethics of prescribing and ORT (Rollin O.); discussion of recommendations; and by-laws.

**Next Meeting Date:     June 12<sup>th</sup> (May go to 3:30 pm, lots of content.)**